Related Experiment Videos

[Basic studies of cefotiam (author's transl)]

Insights

Cefotiam (CTM) pharmacokinetics in children show rapid serum level decline after IV injection and drip infusion, with half-lives around 1-1.2 hours. Urinary excretion averages 45% over 6 hours, with no bioactive metabolites detected.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Antibiotic Research

Context:

  • Cefotiam (CTM) is a cephalosporin antibiotic.
  • Understanding CTM pharmacokinetics is crucial for pediatric dosing.
  • Basic pharmacokinetic studies provide foundational data for clinical application.

Purpose:

  • To determine the serum levels and urinary excretion of cefotiam (CTM) in children following intravenous injection and drip infusion.
  • To assess the serum half-life and identify any bioactive metabolites of CTM.
  • To establish pharmacokinetic profiles for CTM in a pediatric population.

Summary:

  • Following a single intravenous injection of 40 mg/kg CTM, serum levels declined rapidly with a beta-phase half-life of approximately 1.2 hours. Mean urinary excretion was 45.7% over 6 hours.
  • A 1-hour drip infusion of 40 mg/kg CTM resulted in a similar rapid decline in serum levels, with a beta-phase half-life of approximately 1.0 hour. Mean urinary excretion was 48.7% over 6 hours.
  • No bioactive metabolites of CTM were detected in serum or urine after administration at the studied dose.

Impact:

  • Provides essential pharmacokinetic data for cefotiam (CTM) in pediatric patients.
  • Informs appropriate dosage adjustments and administration routes for CTM in children.
  • Contributes to the safe and effective use of cefotiam (CTM) in pediatric infectious disease management.

Related Concept Videos